JP2013510133A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510133A5 JP2013510133A5 JP2012537454A JP2012537454A JP2013510133A5 JP 2013510133 A5 JP2013510133 A5 JP 2013510133A5 JP 2012537454 A JP2012537454 A JP 2012537454A JP 2012537454 A JP2012537454 A JP 2012537454A JP 2013510133 A5 JP2013510133 A5 JP 2013510133A5
- Authority
- JP
- Japan
- Prior art keywords
- chromen
- amino
- pyrazolo
- pyrimidin
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 150000002431 hydrogen Chemical group 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- -1 alkyl hydrogen Chemical compound 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- YZRUPFZRJYBQTF-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-methyl-2h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3NN=C(C)C3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 YZRUPFZRJYBQTF-UHFFFAOYSA-N 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 150000002357 guanidines Chemical class 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- HLYJVSITVHYMGF-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-methyl-1h-indol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3NC=C(C)C3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HLYJVSITVHYMGF-UHFFFAOYSA-N 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- DEMNUISBUXJRNU-UHFFFAOYSA-N 2-(3-fluorophenyl)chromen-4-one Chemical compound FC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1 DEMNUISBUXJRNU-UHFFFAOYSA-N 0.000 claims 1
- LRUBYSGPYGZTCW-UHFFFAOYSA-N 2-(benzimidazol-1-ylmethyl)-3-phenylchromen-4-one Chemical compound C1=NC2=CC=CC=C2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 LRUBYSGPYGZTCW-UHFFFAOYSA-N 0.000 claims 1
- FUXPWOAXFPXFQM-UHFFFAOYSA-N 2-(benzimidazol-1-ylmethyl)-6-bromo-3-phenylchromen-4-one Chemical compound O=C1C2=CC(Br)=CC=C2OC(CN2C3=CC=CC=C3N=C2)=C1C1=CC=CC=C1 FUXPWOAXFPXFQM-UHFFFAOYSA-N 0.000 claims 1
- KNLDQJQMLSCBSE-UHFFFAOYSA-N 2-(imidazol-1-ylmethyl)-3-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(C=2C=CC=CC=2)=C1CN1C=CN=C1 KNLDQJQMLSCBSE-UHFFFAOYSA-N 0.000 claims 1
- GUJVVYUMNWOSAM-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)-3-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(C=2C=CC=CC=2)=C1CN1CCOCC1 GUJVVYUMNWOSAM-UHFFFAOYSA-N 0.000 claims 1
- OPKKWFXLIDOABY-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)-3-phenylchromen-4-one;hydrochloride Chemical compound Cl.O1C2=CC=CC=C2C(=O)C(C=2C=CC=CC=2)=C1CN1CCOCC1 OPKKWFXLIDOABY-UHFFFAOYSA-N 0.000 claims 1
- AYRISEUMQZXCRR-UHFFFAOYSA-N 2-[(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)methyl]-3-phenylchromen-4-one Chemical compound N1=C(I)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 AYRISEUMQZXCRR-UHFFFAOYSA-N 0.000 claims 1
- LDLONLGMHQZNEZ-UHFFFAOYSA-N 2-[(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)methyl]-6-fluoro-3-phenylchromen-4-one Chemical compound N1=C(I)C=2C(N)=NC=NC=2N1CC=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC=C1 LDLONLGMHQZNEZ-UHFFFAOYSA-N 0.000 claims 1
- NTGZDSWGOWEOGR-UHFFFAOYSA-N 2-[(4-amino-3-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-1-yl)methyl]-3-phenylchromen-4-one Chemical compound N1=C(C=2C=NC=CC=2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 NTGZDSWGOWEOGR-UHFFFAOYSA-N 0.000 claims 1
- MUEWLASOJKNMNL-UHFFFAOYSA-N 2-[(4-aminopyrazolo[3,4-d]pyrimidin-1-yl)methyl]-6-bromo-3-phenylchromen-4-one Chemical compound N1=CC=2C(N)=NC=NC=2N1CC=1OC2=CC=C(Br)C=C2C(=O)C=1C1=CC=CC=C1 MUEWLASOJKNMNL-UHFFFAOYSA-N 0.000 claims 1
- NXTSIMDKVIAFFO-UHFFFAOYSA-N 2-[(4-methylbenzimidazol-1-yl)methyl]-3-phenylchromen-4-one Chemical compound C1=NC=2C(C)=CC=CC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 NXTSIMDKVIAFFO-UHFFFAOYSA-N 0.000 claims 1
- YXAHXAJHKGKKHF-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methyl]-3-(2-fluorophenyl)chromen-4-one Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1F YXAHXAJHKGKKHF-UHFFFAOYSA-N 0.000 claims 1
- JSWRDBXIUPWLOB-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 JSWRDBXIUPWLOB-UHFFFAOYSA-N 0.000 claims 1
- IEBKPGFBYUVXHF-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methyl]-3-(4-fluorophenyl)chromen-4-one Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=C(F)C=C1 IEBKPGFBYUVXHF-UHFFFAOYSA-N 0.000 claims 1
- MJUTUKAHFNMZCJ-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methyl]-3-phenylchromen-4-one Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 MJUTUKAHFNMZCJ-UHFFFAOYSA-N 0.000 claims 1
- LUGWDWISIUMJDF-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methyl]-6-bromo-3-(2-fluorophenyl)chromen-4-one Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1OC2=CC=C(Br)C=C2C(=O)C=1C1=CC=CC=C1F LUGWDWISIUMJDF-UHFFFAOYSA-N 0.000 claims 1
- TWVTUTIJEJURNK-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methyl]-6-bromo-3-(2-methylphenyl)chromen-4-one Chemical compound CC1=CC=CC=C1C(C(C1=CC(Br)=CC=C1O1)=O)=C1CN1C2=NC=NC(N)=C2N=C1 TWVTUTIJEJURNK-UHFFFAOYSA-N 0.000 claims 1
- CXQQTVRXULNEFK-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methyl]-6-bromo-3-(4-fluorophenyl)chromen-4-one Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1OC2=CC=C(Br)C=C2C(=O)C=1C1=CC=C(F)C=C1 CXQQTVRXULNEFK-UHFFFAOYSA-N 0.000 claims 1
- RVTDWEOFIDCTBZ-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methyl]-6-bromo-3-phenylchromen-4-one Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1OC2=CC=C(Br)C=C2C(=O)C=1C1=CC=CC=C1 RVTDWEOFIDCTBZ-UHFFFAOYSA-N 0.000 claims 1
- PHQZPXCGTYJFLH-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC(F)=C1 PHQZPXCGTYJFLH-UHFFFAOYSA-N 0.000 claims 1
- XUDDRUSOJKAJIN-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methyl]-6-fluoro-3-phenylchromen-4-one Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC=C1 XUDDRUSOJKAJIN-UHFFFAOYSA-N 0.000 claims 1
- PIOYUNFOAWXYMM-UHFFFAOYSA-N 2-[(6-aminopurin-9-yl)methyl]-6-methoxy-3-phenylchromen-4-one Chemical compound O=C1C2=CC(OC)=CC=C2OC(CN2C3=NC=NC(N)=C3N=C2)=C1C1=CC=CC=C1 PIOYUNFOAWXYMM-UHFFFAOYSA-N 0.000 claims 1
- NXBXHXMMRGBCBG-UHFFFAOYSA-N 2-[(6-chloropurin-9-yl)methyl]-3-phenylchromen-4-one Chemical compound C1=NC=2C(Cl)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 NXBXHXMMRGBCBG-UHFFFAOYSA-N 0.000 claims 1
- MBKCAWRSKHQVHJ-UHFFFAOYSA-N 2-[1-(4-amino-3-dibenzofuran-4-ylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=3OC4=CC=CC=C4C=3C=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 MBKCAWRSKHQVHJ-UHFFFAOYSA-N 0.000 claims 1
- PGQBFCKXKYQUTK-UHFFFAOYSA-N 2-[1-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(I)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 PGQBFCKXKYQUTK-UHFFFAOYSA-N 0.000 claims 1
- YDHHYLZYPOHZNT-UHFFFAOYSA-N 2-[1-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-phenylchromen-4-one Chemical compound N1=C(I)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 YDHHYLZYPOHZNT-UHFFFAOYSA-N 0.000 claims 1
- VLXZCNOMJWCTLT-UHFFFAOYSA-N 2-[1-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(I)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC(F)=C1 VLXZCNOMJWCTLT-UHFFFAOYSA-N 0.000 claims 1
- DNGOOLAROADMJS-UHFFFAOYSA-N 2-[1-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-fluoro-3-phenylchromen-4-one Chemical compound N1=C(I)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC=C1 DNGOOLAROADMJS-UHFFFAOYSA-N 0.000 claims 1
- NPBXYLBOCFZDDW-UHFFFAOYSA-N 2-[1-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)propyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(I)C2=C(N)N=CN=C2N1C(CC)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 NPBXYLBOCFZDDW-UHFFFAOYSA-N 0.000 claims 1
- FPFWFNWLFRSIFI-UHFFFAOYSA-N 2-[1-(4-amino-3-pyrimidin-5-ylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=NC=NC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 FPFWFNWLFRSIFI-UHFFFAOYSA-N 0.000 claims 1
- TUNPHVBQBNZERQ-UHFFFAOYSA-N 2-[1-(4-aminopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-phenylchromen-4-one Chemical compound N1=CC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 TUNPHVBQBNZERQ-UHFFFAOYSA-N 0.000 claims 1
- JJGUSBYXXDVDIV-UHFFFAOYSA-N 2-[1-(4-aminopyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-6-bromo-3-phenylchromen-4-one Chemical compound N1=CC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=C(Br)C=C2C(=O)C=1C1=CC=CC=C1 JJGUSBYXXDVDIV-UHFFFAOYSA-N 0.000 claims 1
- XVTASTKBMBXUKM-UHFFFAOYSA-N 2-[1-(4-chloropyrazolo[3,4-b]pyridin-1-yl)ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=CC2=C(Cl)C=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 XVTASTKBMBXUKM-UHFFFAOYSA-N 0.000 claims 1
- TTWOOLOPDWENNU-UHFFFAOYSA-N 2-[1-(4-chloropyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=CC2=C(Cl)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 TTWOOLOPDWENNU-UHFFFAOYSA-N 0.000 claims 1
- QXVNPMGNZYNOFF-UHFFFAOYSA-N 2-[1-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=CC2=C(Cl)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 QXVNPMGNZYNOFF-UHFFFAOYSA-N 0.000 claims 1
- WENARJGEOUWONT-UHFFFAOYSA-N 2-[1-(4-chloropyrrolo[3,2-d]pyrimidin-5-yl)ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=CC2=NC=NC(Cl)=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 WENARJGEOUWONT-UHFFFAOYSA-N 0.000 claims 1
- WHMLNVHHFADXAM-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)ethyl]-3-(2-fluorophenyl)chromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1F WHMLNVHHFADXAM-UHFFFAOYSA-N 0.000 claims 1
- PDXGAHQJUUWJMH-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)ethyl]-3-(2-methylphenyl)chromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1C PDXGAHQJUUWJMH-UHFFFAOYSA-N 0.000 claims 1
- WRBMZZRBXMEGAS-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)ethyl]-3-(3,5-difluorophenyl)chromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC(F)=CC(F)=C1 WRBMZZRBXMEGAS-UHFFFAOYSA-N 0.000 claims 1
- LQJLKCJAFNRSIS-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 LQJLKCJAFNRSIS-UHFFFAOYSA-N 0.000 claims 1
- GUTNLRCCANXFTG-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)ethyl]-3-(4-fluorophenyl)chromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=C(F)C=C1 GUTNLRCCANXFTG-UHFFFAOYSA-N 0.000 claims 1
- WCVFGPPHHCNTBO-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)ethyl]-3-phenylchromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 WCVFGPPHHCNTBO-UHFFFAOYSA-N 0.000 claims 1
- DDYHHXKNVJDMEG-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)ethyl]-6-bromo-3-(2-fluorophenyl)chromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=C(Br)C=C2C(=O)C=1C1=CC=CC=C1F DDYHHXKNVJDMEG-UHFFFAOYSA-N 0.000 claims 1
- MQUMBWSSTOIBTG-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)ethyl]-6-bromo-3-phenylchromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=C(Br)C=C2C(=O)C=1C1=CC=CC=C1 MQUMBWSSTOIBTG-UHFFFAOYSA-N 0.000 claims 1
- SPSNKUIKGMDEJD-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)ethyl]-6-fluoro-3-(2-fluorophenyl)chromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC=C1F SPSNKUIKGMDEJD-UHFFFAOYSA-N 0.000 claims 1
- PCVWAGVDVPMLSM-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC(F)=C1 PCVWAGVDVPMLSM-UHFFFAOYSA-N 0.000 claims 1
- PPQTZUGSIRZEIJ-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)ethyl]-6-fluoro-3-phenylchromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(C)C=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC=C1 PPQTZUGSIRZEIJ-UHFFFAOYSA-N 0.000 claims 1
- RBOOUDKSRYUAHZ-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)propyl]-3-(2-fluorophenyl)chromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(CC)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1F RBOOUDKSRYUAHZ-UHFFFAOYSA-N 0.000 claims 1
- ZTQWYVKRUMGVGU-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)propyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(CC)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 ZTQWYVKRUMGVGU-UHFFFAOYSA-N 0.000 claims 1
- UYWOEDSZTCMFHJ-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)propyl]-3-(4-fluorophenyl)chromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(CC)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=C(F)C=C1 UYWOEDSZTCMFHJ-UHFFFAOYSA-N 0.000 claims 1
- MIAMNONKYCHXOR-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)propyl]-3-phenylchromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(CC)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 MIAMNONKYCHXOR-UHFFFAOYSA-N 0.000 claims 1
- ANASCSCDTHHCTQ-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)propyl]-6-fluoro-3-phenylchromen-4-one Chemical compound C1=NC2=C(N)N=CN=C2N1C(CC)C=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC=C1 ANASCSCDTHHCTQ-UHFFFAOYSA-N 0.000 claims 1
- WTOFSHVCFTVROT-UHFFFAOYSA-N 2-[1-[3-(4-acetylphenyl)-4-aminopyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=CC(=CC=2)C(C)=O)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 WTOFSHVCFTVROT-UHFFFAOYSA-N 0.000 claims 1
- KMGFVPJVXGLYKF-UHFFFAOYSA-N 2-[1-[4-amino-3-(1,3-dimethylindazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3N(C)N=C(C)C3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 KMGFVPJVXGLYKF-UHFFFAOYSA-N 0.000 claims 1
- NHWATMCZOFXVFA-UHFFFAOYSA-N 2-[1-[4-amino-3-(1-benzothiophen-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2SC3=CC=CC=C3C=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 NHWATMCZOFXVFA-UHFFFAOYSA-N 0.000 claims 1
- QMSGHMSDKYEFBC-UHFFFAOYSA-N 2-[1-[4-amino-3-(1-benzothiophen-3-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C3=CC=CC=C3SC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 QMSGHMSDKYEFBC-UHFFFAOYSA-N 0.000 claims 1
- OXNJJFOPTHHSKM-UHFFFAOYSA-N 2-[1-[4-amino-3-(1-benzylpyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C2=CN(CC=3C=CC=CC=3)N=C2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 OXNJJFOPTHHSKM-UHFFFAOYSA-N 0.000 claims 1
- RYHWOVPFDPFFFC-UHFFFAOYSA-N 2-[1-[4-amino-3-(1-methylpyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C2=CN(C)N=C2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 RYHWOVPFDPFFFC-UHFFFAOYSA-N 0.000 claims 1
- YADMBQDAPMBJPL-UHFFFAOYSA-N 2-[1-[4-amino-3-(1H-pyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C2=CNN=C2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 YADMBQDAPMBJPL-UHFFFAOYSA-N 0.000 claims 1
- OBYQJRVAYOCOHS-UHFFFAOYSA-N 2-[1-[4-amino-3-(1H-pyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-phenylchromen-4-one Chemical compound N1=C(C2=CNN=C2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 OBYQJRVAYOCOHS-UHFFFAOYSA-N 0.000 claims 1
- CFDJNGSAXMSCAB-UHFFFAOYSA-N 2-[1-[4-amino-3-(1h-indazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 CFDJNGSAXMSCAB-UHFFFAOYSA-N 0.000 claims 1
- SULMZJPPHJCQAG-UHFFFAOYSA-N 2-[1-[4-amino-3-(1h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3NN=CC3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 SULMZJPPHJCQAG-UHFFFAOYSA-N 0.000 claims 1
- IFBIAELGPWWSIN-UHFFFAOYSA-N 2-[1-[4-amino-3-(1h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-phenylchromen-4-one Chemical compound N1=C(C=2C=C3NN=CC3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 IFBIAELGPWWSIN-UHFFFAOYSA-N 0.000 claims 1
- JLFPEPJISNHSFG-UHFFFAOYSA-N 2-[1-[4-amino-3-(1h-indol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3C=CNC3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 JLFPEPJISNHSFG-UHFFFAOYSA-N 0.000 claims 1
- JSQUPSMNEOFWJL-UHFFFAOYSA-N 2-[1-[4-amino-3-(1h-indol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3NC=CC3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 JSQUPSMNEOFWJL-UHFFFAOYSA-N 0.000 claims 1
- AOXMZECLAXUJAJ-UHFFFAOYSA-N 2-[1-[4-amino-3-(2,3-dihydro-1-benzofuran-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3CCOC3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 AOXMZECLAXUJAJ-UHFFFAOYSA-N 0.000 claims 1
- SHKZPJLCQLDFGC-UHFFFAOYSA-N 2-[1-[4-amino-3-(2,3-dimethylindazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C2=CC3=NN(C)C(C)=C3C=C2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 SHKZPJLCQLDFGC-UHFFFAOYSA-N 0.000 claims 1
- PNFXXEMIFUUZDT-UHFFFAOYSA-N 2-[1-[4-amino-3-(2,4-dimethoxypyrimidin-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound COC1=NC(OC)=NC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 PNFXXEMIFUUZDT-UHFFFAOYSA-N 0.000 claims 1
- VINNLUFXBGOMKO-UHFFFAOYSA-N 2-[1-[4-amino-3-(2-aminopyrimidin-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=NC(N)=NC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 VINNLUFXBGOMKO-UHFFFAOYSA-N 0.000 claims 1
- WDZUIGIYDAIDGH-UHFFFAOYSA-N 2-[1-[4-amino-3-(2-chloro-5-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C(=CC=C(O)C=2)Cl)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 WDZUIGIYDAIDGH-UHFFFAOYSA-N 0.000 claims 1
- KZTWDJBRPHJDFS-UHFFFAOYSA-N 2-[1-[4-amino-3-(2-chloro-5-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound COC1=CC=C(Cl)C(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 KZTWDJBRPHJDFS-UHFFFAOYSA-N 0.000 claims 1
- SBDFBGGLLBNGLI-UHFFFAOYSA-N 2-[1-[4-amino-3-(2-fluoro-5-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound CC(C)OC1=CC=C(F)C(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 SBDFBGGLLBNGLI-UHFFFAOYSA-N 0.000 claims 1
- CGMHDGQXROSQBH-UHFFFAOYSA-N 2-[1-[4-amino-3-(2-methoxypyrimidin-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=NC(OC)=NC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 CGMHDGQXROSQBH-UHFFFAOYSA-N 0.000 claims 1
- MFJQHXYUYKAYAE-UHFFFAOYSA-N 2-[1-[4-amino-3-(2-methyl-3h-benzimidazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3N=C(C)NC3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 MFJQHXYUYKAYAE-UHFFFAOYSA-N 0.000 claims 1
- DOBFXWQOANAAJJ-UHFFFAOYSA-N 2-[1-[4-amino-3-(2-methylpyridin-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(C)N=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 DOBFXWQOANAAJJ-UHFFFAOYSA-N 0.000 claims 1
- DUZVMXWASHURJC-UHFFFAOYSA-N 2-[1-[4-amino-3-(3,4-dihydro-2h-1,5-benzodioxepin-7-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3OCCCOC3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 DUZVMXWASHURJC-UHFFFAOYSA-N 0.000 claims 1
- NDOQLBGVBSTAET-UHFFFAOYSA-N 2-[1-[4-amino-3-(3,4-dihydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(O)C(O)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 NDOQLBGVBSTAET-UHFFFAOYSA-N 0.000 claims 1
- CIBVELZRMDRRJB-UHFFFAOYSA-N 2-[1-[4-amino-3-(3,4-dimethoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 CIBVELZRMDRRJB-UHFFFAOYSA-N 0.000 claims 1
- IJDOFEDUQRJLKN-UHFFFAOYSA-N 2-[1-[4-amino-3-(3,5-difluoro-4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(F)C(O)=C(F)C=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 IJDOFEDUQRJLKN-UHFFFAOYSA-N 0.000 claims 1
- ORQVODPMLSLGJE-UHFFFAOYSA-N 2-[1-[4-amino-3-(3,5-difluoro-4-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC)=C(F)C=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 ORQVODPMLSLGJE-UHFFFAOYSA-N 0.000 claims 1
- XIOJHCARRQDZII-UHFFFAOYSA-N 2-[1-[4-amino-3-(3,5-dimethoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound COC1=CC(OC)=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 XIOJHCARRQDZII-UHFFFAOYSA-N 0.000 claims 1
- KFHJCGXPUWRDGH-UHFFFAOYSA-N 2-[1-[4-amino-3-(3,5-dimethyl-1,2-oxazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C2=C(ON=C2C)C)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 KFHJCGXPUWRDGH-UHFFFAOYSA-N 0.000 claims 1
- UHQKKSUJFKTELT-UHFFFAOYSA-N 2-[1-[4-amino-3-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C2=C(NN=C2C)C)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 UHQKKSUJFKTELT-UHFFFAOYSA-N 0.000 claims 1
- AMHTZVQYUKTAQM-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-chloro-4-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(Cl)C(OC)=CC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 AMHTZVQYUKTAQM-UHFFFAOYSA-N 0.000 claims 1
- GPDSRNILOMHHMY-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-chloro-4-phenylmethoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(Cl)C(OCC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 GPDSRNILOMHHMY-UHFFFAOYSA-N 0.000 claims 1
- BDYPLKRRXQXDOB-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-chloro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 BDYPLKRRXQXDOB-UHFFFAOYSA-N 0.000 claims 1
- VPZUXWMJTOPCOQ-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-chloro-5-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(Cl)C=C(O)C=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 VPZUXWMJTOPCOQ-UHFFFAOYSA-N 0.000 claims 1
- JPIZBWXMSODEOF-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-chloro-5-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound COC1=CC(Cl)=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 JPIZBWXMSODEOF-UHFFFAOYSA-N 0.000 claims 1
- XPMKAPWWVJDMTO-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-ethoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound CCOC1=CC=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 XPMKAPWWVJDMTO-UHFFFAOYSA-N 0.000 claims 1
- NVXZLKSZWIXXBN-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-ethyl-2h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C=1C=C2C(CC)=NNC2=CC=1C(C1=C(N)N=CN=C11)=NN1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 NVXZLKSZWIXXBN-UHFFFAOYSA-N 0.000 claims 1
- CKIXKPSRAAMSMA-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-fluoro-4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(F)C(O)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 CKIXKPSRAAMSMA-UHFFFAOYSA-N 0.000 claims 1
- FHEVWNCATJTNQI-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 FHEVWNCATJTNQI-UHFFFAOYSA-N 0.000 claims 1
- SBQLJRFAKSJIIV-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-fluoro-5-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(F)C=C(O)C=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 SBQLJRFAKSJIIV-UHFFFAOYSA-N 0.000 claims 1
- AMSPHYVCFMBOQP-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-fluoro-5-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound COC1=CC(F)=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 AMSPHYVCFMBOQP-UHFFFAOYSA-N 0.000 claims 1
- KKGZLCIFBMDQFL-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-hydroxy-3-methylbut-1-ynyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-phenylchromen-4-one Chemical compound N1=C(C#CC(C)(C)O)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 KKGZLCIFBMDQFL-UHFFFAOYSA-N 0.000 claims 1
- AYYNAPOYRUSCIA-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(O)C=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 AYYNAPOYRUSCIA-UHFFFAOYSA-N 0.000 claims 1
- OLHGHOXDOPRFKM-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(O)C=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC(F)=C1 OLHGHOXDOPRFKM-UHFFFAOYSA-N 0.000 claims 1
- UJSQOCOZCRWDCK-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-hydroxyprop-1-ynyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C#CCO)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 UJSQOCOZCRWDCK-UHFFFAOYSA-N 0.000 claims 1
- FBEWCILIJXQXCM-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 FBEWCILIJXQXCM-UHFFFAOYSA-N 0.000 claims 1
- BRZJATUQKNKTMQ-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-phenylchromen-4-one Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=CC=CC=3)N=2)=C1 BRZJATUQKNKTMQ-UHFFFAOYSA-N 0.000 claims 1
- ODFOTLWTOFAEPU-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC(F)=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 ODFOTLWTOFAEPU-UHFFFAOYSA-N 0.000 claims 1
- JALHYRCAJISPSK-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-methyl-1h-indol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3C(C)=CNC3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 JALHYRCAJISPSK-UHFFFAOYSA-N 0.000 claims 1
- IZILECHNHHYDBW-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-methyl-2h-indazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3C(C)=NNC3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 IZILECHNHHYDBW-UHFFFAOYSA-N 0.000 claims 1
- GVJSTFKNCWGFNQ-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-methyl-2h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-phenylchromen-4-one Chemical compound N1=C(C=2C=C3NN=C(C)C3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GVJSTFKNCWGFNQ-UHFFFAOYSA-N 0.000 claims 1
- NTIKTXVBWJDGQC-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-methyl-2h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3NN=C(C)C3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC(F)=C1 NTIKTXVBWJDGQC-UHFFFAOYSA-N 0.000 claims 1
- ZKSDGDXGKFQIHY-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-methyl-2h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-phenylchromen-4-one Chemical compound N1=C(C=2C=C3NN=C(C)C3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC=C1 ZKSDGDXGKFQIHY-UHFFFAOYSA-N 0.000 claims 1
- KQWICTOYVIZZNQ-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-methyl-2h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]propyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3NN=C(C)C3=CC=2)C2=C(N)N=CN=C2N1C(CC)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 KQWICTOYVIZZNQ-UHFFFAOYSA-N 0.000 claims 1
- IVPSADBFFXZFDI-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound CC(C)OC1=CC=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 IVPSADBFFXZFDI-UHFFFAOYSA-N 0.000 claims 1
- QBLDOWKUGHZFDJ-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-propoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound CCCOC1=CC=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 QBLDOWKUGHZFDJ-UHFFFAOYSA-N 0.000 claims 1
- CJZZZMGISNRYTE-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-aminophenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=CC(N)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 CJZZZMGISNRYTE-UHFFFAOYSA-N 0.000 claims 1
- DINYZBFXTRKPEP-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-chloro-3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(O)C(Cl)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 DINYZBFXTRKPEP-UHFFFAOYSA-N 0.000 claims 1
- ZJYWZRAWNUJEKZ-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-chloro-3-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(Cl)C(OC)=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 ZJYWZRAWNUJEKZ-UHFFFAOYSA-N 0.000 claims 1
- AZTFVMCIZJWZGQ-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-ethoxy-3-fluorophenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OCC)=CC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 AZTFVMCIZJWZGQ-UHFFFAOYSA-N 0.000 claims 1
- XSHPUOZMLPXKDK-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-ethoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=CC(OCC)=CC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 XSHPUOZMLPXKDK-UHFFFAOYSA-N 0.000 claims 1
- XKXTVKJCTVHECM-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-fluoro-2-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C(=CC(F)=CC=2)O)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 XKXTVKJCTVHECM-UHFFFAOYSA-N 0.000 claims 1
- MMCLUNWEZMQBKS-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-fluoro-2-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound COC1=CC(F)=CC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 MMCLUNWEZMQBKS-UHFFFAOYSA-N 0.000 claims 1
- ZORLBRQMMPZVDI-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-fluoro-3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(O)C(F)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 ZORLBRQMMPZVDI-UHFFFAOYSA-N 0.000 claims 1
- CQVUSIIYIFYUPQ-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-fluoro-3-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC)=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 CQVUSIIYIFYUPQ-UHFFFAOYSA-N 0.000 claims 1
- KAWDGYFZZWQAPX-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=CC(O)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 KAWDGYFZZWQAPX-UHFFFAOYSA-N 0.000 claims 1
- CFDHGHZQANZOIQ-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 CFDHGHZQANZOIQ-UHFFFAOYSA-N 0.000 claims 1
- ZKCRTOZPGSGKQG-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=CC(=CC=2)S(C)(=O)=O)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 ZKCRTOZPGSGKQG-UHFFFAOYSA-N 0.000 claims 1
- XWPUHQXTFNEAQO-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 XWPUHQXTFNEAQO-UHFFFAOYSA-N 0.000 claims 1
- ASDWTQQVKUSQQS-UHFFFAOYSA-N 2-[1-[4-amino-3-(4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=CC(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC=CC=C2O1 ASDWTQQVKUSQQS-UHFFFAOYSA-N 0.000 claims 1
- QJJPVMRHEVOZOW-UHFFFAOYSA-N 2-[1-[4-amino-3-(5-chlorothiophen-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2SC(Cl)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 QJJPVMRHEVOZOW-UHFFFAOYSA-N 0.000 claims 1
- RQVZPWAJWHSYSD-UHFFFAOYSA-N 2-[1-[4-amino-3-(6-ethoxynaphthalen-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=CC2=CC(OCC)=CC=C2C=C1C(C1=C(N)N=CN=C11)=NN1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 RQVZPWAJWHSYSD-UHFFFAOYSA-N 0.000 claims 1
- HWBAQRDRGWKPRF-UHFFFAOYSA-N 2-[1-[4-amino-3-(6-hydroxynaphthalen-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C3C=CC(O)=CC3=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HWBAQRDRGWKPRF-UHFFFAOYSA-N 0.000 claims 1
- LOLSEUUHDYWBFI-UHFFFAOYSA-N 2-[1-[4-amino-3-(6-methoxynaphthalen-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C(C1=C(N)N=CN=C11)=NN1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 LOLSEUUHDYWBFI-UHFFFAOYSA-N 0.000 claims 1
- QMUUANYDBXDVNV-UHFFFAOYSA-N 2-[1-[4-amino-3-(6-morpholin-4-ylpyridin-3-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=NC(=CC=2)N2CCOCC2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 QMUUANYDBXDVNV-UHFFFAOYSA-N 0.000 claims 1
- SHAQDEKUZAXZNE-UHFFFAOYSA-N 2-[1-[4-amino-3-(furan-2-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2OC=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 SHAQDEKUZAXZNE-UHFFFAOYSA-N 0.000 claims 1
- FNZFMFNRQUQGHZ-UHFFFAOYSA-N 2-[1-[4-amino-3-[2-(hydroxymethyl)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C(=CC=CC=2)CO)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 FNZFMFNRQUQGHZ-UHFFFAOYSA-N 0.000 claims 1
- WAXGCFWXLLFLDX-UHFFFAOYSA-N 2-[1-[4-amino-3-[3-(difluoromethoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(OC(F)F)C=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 WAXGCFWXLLFLDX-UHFFFAOYSA-N 0.000 claims 1
- GMWDLMHEXDHTGW-UHFFFAOYSA-N 2-[1-[4-amino-3-[3-(methoxymethyl)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound COCC1=CC=CC(C=2C3=C(N)N=CN=C3N(C(C)C3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 GMWDLMHEXDHTGW-UHFFFAOYSA-N 0.000 claims 1
- DFHBINSLXFDCQF-UHFFFAOYSA-N 2-[1-[4-amino-3-[3-(trifluoromethoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(OC(F)(F)F)C=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 DFHBINSLXFDCQF-UHFFFAOYSA-N 0.000 claims 1
- HQOQLYBWKRGJSW-UHFFFAOYSA-N 2-[1-[4-amino-3-[4-(dimethylamino)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=CC(=CC=2)N(C)C)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HQOQLYBWKRGJSW-UHFFFAOYSA-N 0.000 claims 1
- KFOLFBGBWBBRDF-UHFFFAOYSA-N 2-[1-[4-amino-3-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=CC(OC(F)(F)F)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 KFOLFBGBWBBRDF-UHFFFAOYSA-N 0.000 claims 1
- YDDMFSLDLBFJPA-UHFFFAOYSA-N 2-[1-[4-amino-3-[5-(aminomethyl)thiophen-2-yl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2SC(CN)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 YDDMFSLDLBFJPA-UHFFFAOYSA-N 0.000 claims 1
- HIOYVPPFYAZOAB-UHFFFAOYSA-N 2-[1-[4-amino-3-[5-(hydroxymethyl)thiophen-3-yl]pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(CO)SC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HIOYVPPFYAZOAB-UHFFFAOYSA-N 0.000 claims 1
- IGGSZDBVXFNIPF-UHFFFAOYSA-N 2-[[4-amino-3-(1H-pyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound N1=C(C2=CNN=C2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 IGGSZDBVXFNIPF-UHFFFAOYSA-N 0.000 claims 1
- QZLFDCQGOYUAPF-UHFFFAOYSA-N 2-[[4-amino-3-(1H-pyrazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-6-fluoro-3-phenylchromen-4-one Chemical compound N1=C(C2=CNN=C2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC=C1 QZLFDCQGOYUAPF-UHFFFAOYSA-N 0.000 claims 1
- BNMXDEDATYZUTI-UHFFFAOYSA-N 2-[[4-amino-3-(1h-indazol-4-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 BNMXDEDATYZUTI-UHFFFAOYSA-N 0.000 claims 1
- DSPMEDKWOGLFMH-UHFFFAOYSA-N 2-[[4-amino-3-(1h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound N1=C(C=2C=C3NN=CC3=CC=2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 DSPMEDKWOGLFMH-UHFFFAOYSA-N 0.000 claims 1
- YWAJTRDSPBIHBT-UHFFFAOYSA-N 2-[[4-amino-3-(3,5-difluoro-4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(F)C(O)=C(F)C=2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC(F)=C1 YWAJTRDSPBIHBT-UHFFFAOYSA-N 0.000 claims 1
- UBAIFMORHOZTOK-UHFFFAOYSA-N 2-[[4-amino-3-(3,5-difluoro-4-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC)=C(F)C=C1C(C1=C(N)N=CN=C11)=NN1CC1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 UBAIFMORHOZTOK-UHFFFAOYSA-N 0.000 claims 1
- HFCNWCHEKAHFSJ-UHFFFAOYSA-N 2-[[4-amino-3-(3-aminophenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound NC1=CC=CC(C=2C3=C(N)N=CN=C3N(CC3=C(C(=O)C4=CC=CC=C4O3)C=3C=CC=CC=3)N=2)=C1 HFCNWCHEKAHFSJ-UHFFFAOYSA-N 0.000 claims 1
- VGWQJRGDBYWHPC-UHFFFAOYSA-N 2-[[4-amino-3-(3-fluoro-5-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(F)C=C(O)C=2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 VGWQJRGDBYWHPC-UHFFFAOYSA-N 0.000 claims 1
- PTZNGRKSMAWYFJ-UHFFFAOYSA-N 2-[[4-amino-3-(3-fluoro-5-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound N1=C(C=2C=C(F)C=C(O)C=2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 PTZNGRKSMAWYFJ-UHFFFAOYSA-N 0.000 claims 1
- CTJKGPPVGRIBTL-UHFFFAOYSA-N 2-[[4-amino-3-(3-fluoro-5-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(F)C=C(O)C=2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC(F)=C1 CTJKGPPVGRIBTL-UHFFFAOYSA-N 0.000 claims 1
- DEFYFJDUMZNGRZ-UHFFFAOYSA-N 2-[[4-amino-3-(3-fluoro-5-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound COC1=CC(F)=CC(C=2C3=C(N)N=CN=C3N(CC3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 DEFYFJDUMZNGRZ-UHFFFAOYSA-N 0.000 claims 1
- WLYNJYWCTVTHJA-UHFFFAOYSA-N 2-[[4-amino-3-(3-fluoro-5-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound COC1=CC(F)=CC(C=2C3=C(N)N=CN=C3N(CC3=C(C(=O)C4=CC=CC=C4O3)C=3C=CC=CC=3)N=2)=C1 WLYNJYWCTVTHJA-UHFFFAOYSA-N 0.000 claims 1
- HQKSWGCMRYNXBD-UHFFFAOYSA-N 2-[[4-amino-3-(3-fluoro-5-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound COC1=CC(F)=CC(C=2C3=C(N)N=CN=C3N(CC3=C(C(=O)C4=CC(F)=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 HQKSWGCMRYNXBD-UHFFFAOYSA-N 0.000 claims 1
- BMPPSJSGHPXWEM-UHFFFAOYSA-N 2-[[4-amino-3-(3-fluorophenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound N1=C(C=2C=C(F)C=CC=2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 BMPPSJSGHPXWEM-UHFFFAOYSA-N 0.000 claims 1
- AXTQRIYBBVIIOA-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound N1=C(C=2C=C(O)C=CC=2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 AXTQRIYBBVIIOA-UHFFFAOYSA-N 0.000 claims 1
- XOIXTQRKYMNJID-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound N1=C(C=2C=C(O)C=CC=2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 XOIXTQRKYMNJID-UHFFFAOYSA-N 0.000 claims 1
- MNBIGEFEXDPCBE-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxyprop-1-ynyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound N1=C(C#CCO)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 MNBIGEFEXDPCBE-UHFFFAOYSA-N 0.000 claims 1
- FJELXXKKBCPXLD-UHFFFAOYSA-N 2-[[4-amino-3-(3-hydroxypropyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound N1=C(CCCO)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 FJELXXKKBCPXLD-UHFFFAOYSA-N 0.000 claims 1
- SUORMPWTFOFTCW-UHFFFAOYSA-N 2-[[4-amino-3-(3-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(CC3=C(C(=O)C4=CC=CC=C4O3)C=3C=C(F)C=CC=3)N=2)=C1 SUORMPWTFOFTCW-UHFFFAOYSA-N 0.000 claims 1
- OFAWXEAIXKHVLZ-UHFFFAOYSA-N 2-[[4-amino-3-(3-methoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(CC3=C(C(=O)C4=CC=CC=C4O3)C=3C=CC=CC=3)N=2)=C1 OFAWXEAIXKHVLZ-UHFFFAOYSA-N 0.000 claims 1
- ROTZVQQRRWIHKH-UHFFFAOYSA-N 2-[[4-amino-3-(3-methyl-2h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C=1C=C2C(C)=NNC2=CC=1C(C1=C(N)N=CN=C11)=NN1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 ROTZVQQRRWIHKH-UHFFFAOYSA-N 0.000 claims 1
- OIIZKFYUTZREAR-UHFFFAOYSA-N 2-[[4-amino-3-(3-methyl-2h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound C=1C=C2C(C)=NNC2=CC=1C(C1=C(N)N=CN=C11)=NN1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 OIIZKFYUTZREAR-UHFFFAOYSA-N 0.000 claims 1
- CTWOZELQQJJRFF-UHFFFAOYSA-N 2-[[4-amino-3-(3-methyl-2h-indazol-6-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-6-fluoro-3-phenylchromen-4-one Chemical compound C=1C=C2C(C)=NNC2=CC=1C(C1=C(N)N=CN=C11)=NN1CC=1OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC=C1 CTWOZELQQJJRFF-UHFFFAOYSA-N 0.000 claims 1
- RBPYUIYVYGSPKB-UHFFFAOYSA-N 2-[[4-amino-3-[3-(hydroxymethyl)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-phenylchromen-4-one Chemical compound N1=C(C=2C=C(CO)C=CC=2)C=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 RBPYUIYVYGSPKB-UHFFFAOYSA-N 0.000 claims 1
- JMBFPBNTNUTDLF-UHFFFAOYSA-N 3-(2-fluorophenyl)-2-[(7h-purin-6-ylamino)methyl]chromen-4-one Chemical compound FC1=CC=CC=C1C(C(C1=CC=CC=C1O1)=O)=C1CNC1=NC=NC2=C1N=CN2 JMBFPBNTNUTDLF-UHFFFAOYSA-N 0.000 claims 1
- LEMBJTYNTQDECJ-GFCCVEGCSA-N 3-(3-fluorophenyl)-2-[(1r)-1-(7h-purin-6-ylamino)ethyl]chromen-4-one Chemical compound C=1([C@H](NC=2C=3N=CNC=3N=CN=2)C)OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 LEMBJTYNTQDECJ-GFCCVEGCSA-N 0.000 claims 1
- LEMBJTYNTQDECJ-LBPRGKRZSA-N 3-(3-fluorophenyl)-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]chromen-4-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 LEMBJTYNTQDECJ-LBPRGKRZSA-N 0.000 claims 1
- PZXRCHLNYKHQSM-UHFFFAOYSA-N 3-(3-fluorophenyl)-2-[(7h-purin-6-ylamino)methyl]chromen-4-one Chemical compound FC1=CC=CC(C=2C(C3=CC=CC=C3OC=2CNC=2C=3N=CNC=3N=CN=2)=O)=C1 PZXRCHLNYKHQSM-UHFFFAOYSA-N 0.000 claims 1
- ZGGXQXLFNHDLLG-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-(morpholin-4-ylmethyl)chromen-4-one Chemical compound C1=CC(F)=CC=C1C(C(C1=CC=CC=C1O1)=O)=C1CN1CCOCC1 ZGGXQXLFNHDLLG-UHFFFAOYSA-N 0.000 claims 1
- ITWLQBZRKIGAQY-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-(morpholin-4-ylmethyl)chromen-4-one;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C(C(C1=CC=CC=C1O1)=O)=C1CN1CCOCC1 ITWLQBZRKIGAQY-UHFFFAOYSA-N 0.000 claims 1
- SRPWHIILKXGVEP-UHFFFAOYSA-N 3-[4-amino-1-[1-[3-(3-fluorophenyl)-4-oxochromen-2-yl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-n-cyclopropylbenzamide Chemical compound N1=C(C=2C=C(C=CC=2)C(=O)NC2CC2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 SRPWHIILKXGVEP-UHFFFAOYSA-N 0.000 claims 1
- YDAVFGOHSKDPLG-UHFFFAOYSA-N 3-phenyl-2-(7h-purin-6-ylsulfanylmethyl)chromen-4-one Chemical compound N=1C=NC=2NC=NC=2C=1SCC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 YDAVFGOHSKDPLG-UHFFFAOYSA-N 0.000 claims 1
- OLCAEQPPVVYASY-ZDUSSCGKSA-N 3-phenyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]chromen-4-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 OLCAEQPPVVYASY-ZDUSSCGKSA-N 0.000 claims 1
- XUHCZJLBWDGYEN-UHFFFAOYSA-N 3-phenyl-2-[(7h-purin-6-ylamino)methyl]chromen-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NCC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 XUHCZJLBWDGYEN-UHFFFAOYSA-N 0.000 claims 1
- XIVKKHYUECKZLP-UHFFFAOYSA-N 4-[4-amino-1-[1-[3-(3-fluorophenyl)-4-oxochromen-2-yl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]thiophene-2-carbaldehyde Chemical compound N1=C(C=2C=C(C=O)SC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 XIVKKHYUECKZLP-UHFFFAOYSA-N 0.000 claims 1
- FBQFWYFUWNBDDW-UHFFFAOYSA-N 5-[4-amino-1-[1-[3-(3-fluorophenyl)-4-oxochromen-2-yl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]furan-2-carbaldehyde Chemical compound N1=C(C=2OC(C=O)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 FBQFWYFUWNBDDW-UHFFFAOYSA-N 0.000 claims 1
- OYSBUVSXKYYNMA-UHFFFAOYSA-N 6-bromo-2-(morpholin-4-ylmethyl)-3-phenylchromen-4-one Chemical compound C=1C=CC=CC=1C=1C(=O)C2=CC(Br)=CC=C2OC=1CN1CCOCC1 OYSBUVSXKYYNMA-UHFFFAOYSA-N 0.000 claims 1
- BSTWHUYNOKXPGL-UHFFFAOYSA-N 6-bromo-2-(morpholin-4-ylmethyl)-3-phenylchromen-4-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C=1C(=O)C2=CC(Br)=CC=C2OC=1CN1CCOCC1 BSTWHUYNOKXPGL-UHFFFAOYSA-N 0.000 claims 1
- ZAESDLHDSRHLOH-UHFFFAOYSA-N 6-bromo-2-[(4-methylbenzimidazol-1-yl)methyl]-3-phenylchromen-4-one Chemical compound C1=NC=2C(C)=CC=CC=2N1CC=1OC2=CC=C(Br)C=C2C(=O)C=1C1=CC=CC=C1 ZAESDLHDSRHLOH-UHFFFAOYSA-N 0.000 claims 1
- GGIZECDKZRRWPN-UHFFFAOYSA-N 6-bromo-2-[(6-chloropurin-9-yl)methyl]-3-phenylchromen-4-one Chemical compound C1=NC=2C(Cl)=NC=NC=2N1CC=1OC2=CC=C(Br)C=C2C(=O)C=1C1=CC=CC=C1 GGIZECDKZRRWPN-UHFFFAOYSA-N 0.000 claims 1
- XDWRULCXHCXHRP-UHFFFAOYSA-N 6-bromo-3-(4-fluorophenyl)-2-(morpholin-4-ylmethyl)chromen-4-one Chemical compound C1=CC(F)=CC=C1C(C(C1=CC(Br)=CC=C1O1)=O)=C1CN1CCOCC1 XDWRULCXHCXHRP-UHFFFAOYSA-N 0.000 claims 1
- OKNVSGNYSNPIPD-UHFFFAOYSA-N 6-bromo-3-(4-fluorophenyl)-2-(morpholin-4-ylmethyl)chromen-4-one;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C(C(C1=CC(Br)=CC=C1O1)=O)=C1CN1CCOCC1 OKNVSGNYSNPIPD-UHFFFAOYSA-N 0.000 claims 1
- UWJUUEHCNSBZSK-UHFFFAOYSA-N 6-bromo-3-phenyl-2-(7h-purin-6-ylsulfanylmethyl)chromen-4-one Chemical compound O=C1C2=CC(Br)=CC=C2OC(CSC=2C=3N=CNC=3N=CN=2)=C1C1=CC=CC=C1 UWJUUEHCNSBZSK-UHFFFAOYSA-N 0.000 claims 1
- CCDVYDSKPOSJQL-LBPRGKRZSA-N 6-bromo-3-phenyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]chromen-4-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)OC2=CC=C(Br)C=C2C(=O)C=1C1=CC=CC=C1 CCDVYDSKPOSJQL-LBPRGKRZSA-N 0.000 claims 1
- KXSDOBIWKOBINP-UHFFFAOYSA-N 6-bromo-3-phenyl-2-[(7h-purin-6-ylamino)methyl]chromen-4-one Chemical compound O=C1C2=CC(Br)=CC=C2OC(CNC=2C=3N=CNC=3N=CN=2)=C1C1=CC=CC=C1 KXSDOBIWKOBINP-UHFFFAOYSA-N 0.000 claims 1
- ZXRCPILJODBCHJ-LLVKDONJSA-N 6-fluoro-3-(3-fluorophenyl)-2-[(1r)-1-(7h-purin-6-ylamino)ethyl]chromen-4-one Chemical compound C=1([C@H](NC=2C=3N=CNC=3N=CN=2)C)OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC(F)=C1 ZXRCPILJODBCHJ-LLVKDONJSA-N 0.000 claims 1
- ZXRCPILJODBCHJ-NSHDSACASA-N 6-fluoro-3-(3-fluorophenyl)-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]chromen-4-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC(F)=C1 ZXRCPILJODBCHJ-NSHDSACASA-N 0.000 claims 1
- OQRJJNURZCEMKL-UHFFFAOYSA-N 6-fluoro-3-(3-fluorophenyl)-2-[(7h-purin-6-ylamino)methyl]chromen-4-one Chemical compound FC1=CC=CC(C=2C(C3=CC(F)=CC=C3OC=2CNC=2C=3N=CNC=3N=CN=2)=O)=C1 OQRJJNURZCEMKL-UHFFFAOYSA-N 0.000 claims 1
- JDTCSOLTCLBMKS-UHFFFAOYSA-N 6-fluoro-3-(3-fluorophenyl)-2-[1-(4-methoxyanilino)ethyl]chromen-4-one Chemical compound C1=CC(OC)=CC=C1NC(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 JDTCSOLTCLBMKS-UHFFFAOYSA-N 0.000 claims 1
- YUSZXLCDUDCZGL-LBPRGKRZSA-N 6-fluoro-3-phenyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]chromen-4-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)OC2=CC=C(F)C=C2C(=O)C=1C1=CC=CC=C1 YUSZXLCDUDCZGL-LBPRGKRZSA-N 0.000 claims 1
- YJMCRCOUOLVLCD-UHFFFAOYSA-N 6-fluoro-3-phenyl-2-[(7h-purin-6-ylamino)methyl]chromen-4-one Chemical compound O=C1C2=CC(F)=CC=C2OC(CNC=2C=3N=CNC=3N=CN=2)=C1C1=CC=CC=C1 YJMCRCOUOLVLCD-UHFFFAOYSA-N 0.000 claims 1
- AEVVTGILFZUVRU-UHFFFAOYSA-N 7-[(6-bromo-4-oxo-3-phenylchromen-2-yl)methyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC=1OC2=CC=C(Br)C=C2C(=O)C=1C1=CC=CC=C1 AEVVTGILFZUVRU-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- LSBDFXRDZJMBSC-UHFFFAOYSA-N Amide-Phenylacetic acid Natural products NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 206010062639 Herpes dermatitis Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- LIKGCNJQMKWKIZ-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C2=CC(=C(C(=C2)OC)OC)OC)C(C)C=2OC1=CC=CC=C1C(C2C2=CC(=CC=C2)F)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C2=CC(=C(C(=C2)OC)OC)OC)C(C)C=2OC1=CC=CC=C1C(C2C2=CC(=CC=C2)F)=O LIKGCNJQMKWKIZ-UHFFFAOYSA-N 0.000 claims 1
- AUXRILMOCUSGMO-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C=2CC(C=CC2)(OC)F)C(C)C=2OC1=CC=CC=C1C(C2C2=CC(=CC=C2)F)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C=2CC(C=CC2)(OC)F)C(C)C=2OC1=CC=CC=C1C(C2C2=CC(=CC=C2)F)=O AUXRILMOCUSGMO-UHFFFAOYSA-N 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 241000243985 Onchocerca volvulus Species 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010053869 POEMS syndrome Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010010180 Renal failure complications Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000002250 liver carcinoma Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015270 non-secretory plasma cell myeloma Diseases 0.000 claims 1
- 208000002042 onchocerciasis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- HWCXSZZGMROORD-UHFFFAOYSA-N tert-butyl n-[[5-[4-amino-1-[1-[3-(3-fluorophenyl)-4-oxochromen-2-yl]ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]thiophen-2-yl]methyl]carbamate Chemical compound N1=C(C=2SC(CNC(=O)OC(C)(C)C)=CC=2)C2=C(N)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HWCXSZZGMROORD-UHFFFAOYSA-N 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2690/CHE/2009 | 2009-11-05 | ||
| IN2690CH2009 | 2009-11-05 | ||
| IN1429/CHE/2010 | 2010-05-24 | ||
| IN1429CH2010 | 2010-05-24 | ||
| US36466110P | 2010-07-15 | 2010-07-15 | |
| US61/364,661 | 2010-07-15 | ||
| PCT/IB2010/002804 WO2011055215A2 (en) | 2009-11-05 | 2010-11-03 | Novel kinase modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016027735A Division JP6385966B2 (ja) | 2009-11-05 | 2016-02-17 | 新規キナーゼモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013510133A JP2013510133A (ja) | 2013-03-21 |
| JP2013510133A5 true JP2013510133A5 (https=) | 2013-12-26 |
| JP5889795B2 JP5889795B2 (ja) | 2016-03-22 |
Family
ID=43970461
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537454A Active JP5889795B2 (ja) | 2009-11-05 | 2010-11-03 | 新規キナーゼモジュレーター |
| JP2016027735A Expired - Fee Related JP6385966B2 (ja) | 2009-11-05 | 2016-02-17 | 新規キナーゼモジュレーター |
| JP2018079763A Pending JP2018111727A (ja) | 2009-11-05 | 2018-04-18 | 新規キナーゼモジュレーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016027735A Expired - Fee Related JP6385966B2 (ja) | 2009-11-05 | 2016-02-17 | 新規キナーゼモジュレーター |
| JP2018079763A Pending JP2018111727A (ja) | 2009-11-05 | 2018-04-18 | 新規キナーゼモジュレーター |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US10442783B2 (https=) |
| EP (3) | EP3050876A3 (https=) |
| JP (3) | JP5889795B2 (https=) |
| KR (2) | KR101821768B1 (https=) |
| CN (2) | CN102812013B (https=) |
| AP (1) | AP2012006294A0 (https=) |
| AU (2) | AU2010316780B2 (https=) |
| BR (1) | BR112012010640A2 (https=) |
| CA (2) | CA2779574C (https=) |
| CO (1) | CO6551721A2 (https=) |
| CY (1) | CY1119766T1 (https=) |
| DK (1) | DK2496567T3 (https=) |
| EA (2) | EA036876B1 (https=) |
| ES (1) | ES2651682T3 (https=) |
| HR (1) | HRP20171537T1 (https=) |
| HU (1) | HUE035059T2 (https=) |
| IL (1) | IL219585A (https=) |
| LT (1) | LT2496567T (https=) |
| MX (1) | MX352661B (https=) |
| MY (1) | MY173795A (https=) |
| NZ (1) | NZ599830A (https=) |
| PH (2) | PH12012500901A1 (https=) |
| PL (1) | PL2496567T3 (https=) |
| PT (1) | PT2496567T (https=) |
| RS (1) | RS56432B1 (https=) |
| SG (1) | SG10201500895XA (https=) |
| SI (1) | SI2496567T1 (https=) |
| SM (1) | SMT201700468T1 (https=) |
| WO (1) | WO2011055215A2 (https=) |
| ZA (1) | ZA201203849B (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5599783B2 (ja) | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
| KR102263079B1 (ko) * | 2009-11-05 | 2021-06-10 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 벤조피란 키나제 조절제 |
| PH12012500901A1 (en) | 2009-11-05 | 2016-08-05 | Rhizen Pharmaceuticals Sa | Novel benzopyran kinase modulators |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| HRP20190128T1 (hr) | 2011-05-04 | 2019-03-08 | Rhizen Pharmaceuticals S.A. | Novi spojevi kao modulatori protein kinaza |
| US9138436B2 (en) | 2011-07-13 | 2015-09-22 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| KR102507287B1 (ko) | 2011-09-02 | 2023-03-07 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| WO2013090725A1 (en) * | 2011-12-15 | 2013-06-20 | Philadelphia Health & Education Corporation | NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF |
| DK2790705T3 (en) | 2011-12-15 | 2018-03-12 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
| CA2868026C (en) | 2012-03-23 | 2021-02-16 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| US10130635B2 (en) * | 2012-05-04 | 2018-11-20 | Rhizen Pharmaceuticals Sa | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals |
| AU2013255469B2 (en) * | 2012-05-04 | 2017-10-12 | Rhizen Pharmaceuticals Sa | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals |
| CN109970742A (zh) | 2012-07-04 | 2019-07-05 | 理森制药股份公司 | 选择性PI3Kδ抑制剂 |
| CA3128846C (en) * | 2012-07-27 | 2025-05-06 | Sato Pharmaceutical Co. Ltd. | COMPOSITE OF DIFLUOROMETHYLENE |
| US20150258127A1 (en) * | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| SG11201503393SA (en) * | 2012-11-02 | 2015-06-29 | Tg Therapeutics Inc | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor |
| US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
| WO2014195888A1 (en) * | 2013-06-07 | 2014-12-11 | Rhizen Pharmaceuticals Sa | Dual selective pi3 delta and gamma kinase inhibitors |
| CN105431437B (zh) | 2013-07-02 | 2020-03-10 | 理森制药股份公司 | PI3K蛋白激酶抑制剂，特别是δ抑制剂和/或γ抑制剂 |
| TWI672297B (zh) * | 2013-12-18 | 2019-09-21 | 義大利商吉斯藥品公司 | 作為磷脂肌醇－３－激酶抑制劑之異唏衍生物 |
| CA2934700A1 (en) * | 2014-01-06 | 2015-07-09 | Rhizen Pharmaceuticals Sa | Glutaminase inhibitors |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| AU2015278699B2 (en) * | 2014-06-27 | 2019-10-31 | Rhizen Pharmaceuticals Sa | Substituted chromene derivatives as selective dual inhibitors of PI3 delta and gamma protein kinases |
| CN105315252A (zh) * | 2014-07-03 | 2016-02-10 | 中国药科大学 | 基于3-羟基色原酮结构的Raf激酶抑制剂及其制备方法和用途 |
| MX2017000208A (es) | 2014-07-04 | 2017-05-01 | Lupin Ltd | Derivados de quinolizinona como inhibidores de pi3k. |
| US10786504B2 (en) * | 2014-09-03 | 2020-09-29 | Rhizen Pharmaceuticals Sa | Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and a corticosteroid |
| US9950194B2 (en) | 2014-09-09 | 2018-04-24 | Mevion Medical Systems, Inc. | Patient positioning system |
| SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
| CN106008479B (zh) * | 2015-03-06 | 2020-01-10 | 南京圣和药业股份有限公司 | 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用 |
| US9968604B2 (en) * | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
| GB201506786D0 (en) * | 2015-04-21 | 2015-06-03 | Ucb Biopharma Sprl | Therapeutic use |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US20180215727A1 (en) * | 2015-07-23 | 2018-08-02 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| ES2880766T3 (es) | 2016-02-09 | 2021-11-25 | Pharmakea Inc | Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos |
| GB201602527D0 (en) * | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| DK3442980T3 (da) | 2016-04-15 | 2021-08-30 | Cancer Research Tech Ltd | Heterocykliske forbindelser som ret-kinase-hæmmere |
| LT3442535T (lt) | 2016-04-15 | 2022-10-25 | Cancer Research Technology Limited | Heterocikliniai junginiai kaip ret kinazės inhibitoriai |
| AU2017268839A1 (en) | 2016-05-27 | 2018-11-29 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders |
| CN110191720A (zh) | 2016-09-09 | 2019-08-30 | Tg治疗有限公司 | 用于治疗血液学癌症的抗-CD20抗体、PI 3激酶-δ抑制剂以及抗-PD-1或抗-PD-L1抗体的组合 |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| GB201705971D0 (en) * | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| CN111770776A (zh) * | 2017-12-06 | 2020-10-13 | 瑞真药业公司 | 治疗外周t细胞淋巴瘤和皮肤t细胞淋巴瘤的组合物和方法 |
| WO2019143991A1 (en) * | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
| CA3101323A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
| WO2020038394A1 (zh) * | 2018-08-21 | 2020-02-27 | 南京明德新药研发有限公司 | 吡唑并嘧啶衍生物及其作为pi3k抑制剂的应用 |
| EP3849986B1 (en) | 2018-09-10 | 2022-06-08 | Array Biopharma, Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| AU2020252904A1 (en) | 2019-04-04 | 2021-11-18 | Chiesi Farmaceutici S.P.A. | Isochromene derivatives as phosphoinositide 3-kinases inhibitors |
| US12516038B2 (en) | 2020-03-31 | 2026-01-06 | Janssen Pharmaceutica Nv | Inhibitors of antigen presentation by HLA-DR |
| AR121719A1 (es) * | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| ES3037417T3 (en) | 2020-05-14 | 2025-10-01 | Rhizen Pharmaceuticals Ag | Purine derivatives as sik-3 inhibitors |
| CN111499619B (zh) * | 2020-05-20 | 2021-05-18 | 温州医科大学附属第一医院 | 一种治疗肝纤维化的药物及其制备方法 |
| US20220143026A1 (en) | 2020-11-12 | 2022-05-12 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
| CN113337457B (zh) * | 2021-06-01 | 2024-06-25 | 澳门大学 | 一种无血清调控干细胞的细胞状态的方法以及调节剂的应用 |
| WO2023123742A1 (zh) * | 2021-12-31 | 2023-07-06 | 同润生物医药(上海)有限公司 | PI3Kδ/γ双重抑制剂化合物的半富马酸盐结晶及其制备方法 |
| CN116410194B (zh) * | 2021-12-31 | 2025-07-18 | 同润生物医药(上海)有限公司 | 一种苯磺酸盐结晶及其制备方法 |
| WO2023130334A1 (zh) * | 2022-01-07 | 2023-07-13 | 同润生物医药(上海)有限公司 | 一种色烯-4-酮化合物及其中间体的制备方法 |
| CN116444521A (zh) * | 2022-01-07 | 2023-07-18 | 同润生物医药(上海)有限公司 | 一种色烯-4-酮化合物及其中间体的制备方法 |
| CN114891005B (zh) * | 2022-03-30 | 2024-01-19 | 武汉九州钰民医药科技有限公司 | 一种乌帕利斯对甲苯磺酸盐的制备工艺 |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| CN121219300A (zh) * | 2023-03-15 | 2025-12-26 | An2治疗公司 | 化学化合物 |
Family Cites Families (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1223531A (fr) * | 1959-01-29 | 1960-06-17 | Rech S & Documentation Chimiqu | Application des oxalates d'aryle à un nouveau mode de préparation des esters gamma-benzopyrone-2-carboxyliques |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5126877A (ja) * | 1974-08-21 | 1976-03-05 | Tanabe Seiyaku Co | Shinkikisantonjudotaino seiho |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| FR2516922A1 (fr) | 1981-11-25 | 1983-05-27 | Lipha | Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| JPS62201882A (ja) | 1985-11-18 | 1987-09-05 | Yamanouchi Pharmaceut Co Ltd | イソフラボン誘導体 |
| AT386415B (de) | 1986-05-16 | 1988-08-25 | Greber Gerd | Verfahren zur herstellung von neuen loeslichen und/oder schmelzbaren polyimiden und polyamidimiden |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| EP0545913B1 (en) | 1986-08-18 | 1999-02-24 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
| US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| JPH0817590A (ja) | 1994-06-28 | 1996-01-19 | Achilles Corp | 除電ロール |
| JPH08176070A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | ジデプシド誘導体及びｐｉ３キナーゼ阻害剤 |
| JPH08175990A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Ｐｉ３キナーゼ阻害剤とその製造法 |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| DK0821671T3 (da) | 1995-04-20 | 2001-04-23 | Pfizer | Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer |
| GB9521987D0 (en) | 1995-10-26 | 1996-01-03 | Ludwig Inst Cancer Res | Phosphoinositide 3-kinase modulators |
| DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Agouron Pharmaceuticals, Inc. | Matrix-metalloprotease Inhibitoren |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| WO1998007697A1 (en) | 1996-08-23 | 1998-02-26 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| IT1289154B1 (it) | 1997-01-03 | 1998-09-29 | Chiesi Farma Spa | Derivati di isoflavone loro preparazione e loro impiego terapeutico |
| WO1998030566A1 (en) | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| EP0977733B1 (en) | 1997-02-03 | 2003-09-03 | Pfizer Products Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| EA002546B1 (ru) | 1997-02-11 | 2002-06-27 | Пфайзер Инк. | Производные арилсульфонилгидроксамовой кислоты |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| AU730248B2 (en) | 1997-08-08 | 2001-03-01 | Pfizer Products Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| DK1004578T3 (da) | 1998-11-05 | 2004-06-28 | Pfizer Prod Inc | 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater |
| BR0008379A (pt) | 1999-02-22 | 2002-09-24 | Biotechnolog Forschung Gmbh | Epotilonas modificadas em c-21 |
| US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
| JP2001247477A (ja) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | 抗腫瘍剤 |
| ES2788383T3 (es) | 2000-04-25 | 2020-10-21 | Icos Corp | Inhibidores de delta fosfatidilo-inositol 3-quinasa humana |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| DE60203260T2 (de) | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| US20040242545A1 (en) | 2001-07-26 | 2004-12-02 | Santen Phamaceutical Co., Ltd. | Remedy for glaucoma comprising as the active ingredient compound having p13 kinase inhibitory effect |
| US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
| US6894055B2 (en) | 2001-10-24 | 2005-05-17 | Iconix Pharmaceuticals Inc. | Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase |
| AU2002349912A1 (en) | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| AU2002356871A1 (en) | 2001-10-30 | 2003-05-12 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| AU2003234733B2 (en) * | 2002-04-17 | 2009-01-29 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
| CN1681811B (zh) | 2002-07-10 | 2010-05-26 | 默克雪兰诺有限公司 | 唑烷酮-乙烯基稠合的-苯衍生物 |
| JP2006500327A (ja) | 2002-07-10 | 2006-01-05 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 精子の運動性を増大させるための化合物の使用 |
| JP4646626B2 (ja) * | 2002-08-16 | 2011-03-09 | アストラゼネカ アクチボラグ | ホスホイノシチド３−キナーゼβの阻害 |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| US7601724B2 (en) | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US7605155B2 (en) | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| WO2004072029A2 (en) | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
| GB0305152D0 (en) * | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
| KR20070087266A (ko) * | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| CN1809536A (zh) | 2003-04-24 | 2006-07-26 | 麦克公司 | Akt活性抑制剂 |
| DE602004027737D1 (de) | 2003-07-30 | 2010-07-29 | Roche Diagnostics Gmbh | Neue chemilumineszenzverbindungen und ihre verwendung |
| WO2005013982A1 (en) | 2003-08-06 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| WO2006036883A2 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| FR2882751B1 (fr) | 2005-03-04 | 2007-09-14 | Aventis Pharma Sa | Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, procede de preparation, compositions les contenant et utilisation |
| US20090258852A1 (en) | 2005-07-08 | 2009-10-15 | Arrington Kenneth L | Inhibitors of Checkpoint Kinases |
| MX2008002165A (es) | 2005-08-16 | 2008-04-29 | Irm Llc | Compuestos y composiciones como inhibidores de la proteina cinasa. |
| PT1937671E (pt) | 2005-09-06 | 2010-03-12 | Smithkline Beecham Corp | Compostos de benzimidazole tiofeno como inibidores de plk |
| CN101395155A (zh) | 2005-10-07 | 2009-03-25 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| US7790739B2 (en) | 2005-10-21 | 2010-09-07 | Merck & Co., Inc. and Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| MY149143A (en) | 2006-01-18 | 2013-07-15 | Amgen Inc | Thiazole compounds as protien kinase b (pkb) inhibitors |
| JP2009528335A (ja) | 2006-03-02 | 2009-08-06 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| US20090247554A1 (en) | 2006-03-30 | 2009-10-01 | Takeda San Diego, Inc. | Kinase inhibitors |
| WO2007114926A2 (en) * | 2006-04-04 | 2007-10-11 | The Regents Of The University Of California | Kinase antagonists |
| MX2008013578A (es) | 2006-04-26 | 2009-03-23 | Hoffmann La Roche | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). |
| CN101511840A (zh) | 2006-04-26 | 2009-08-19 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物及其使用方法 |
| WO2007132867A1 (ja) | 2006-05-15 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 癌の予防及び治療剤 |
| GB0610243D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| EP2049106A2 (en) | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US7605160B2 (en) | 2006-08-09 | 2009-10-20 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2008032072A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| WO2008070740A1 (en) | 2006-12-07 | 2008-06-12 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| ES2571028T3 (es) | 2006-12-07 | 2016-05-23 | Genentech Inc | Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso |
| RS53151B (sr) | 2007-03-23 | 2014-06-30 | Amgen Inc. | 3-supstituisani derivati hinolina ili hinoksalina i njihova upotreba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k) |
| PE20090288A1 (es) | 2007-05-10 | 2009-04-03 | Smithkline Beecham Corp | Derivados de quinoxalina como inhibidores de la pi3 quinasa |
| EP2173338A1 (en) | 2007-07-06 | 2010-04-14 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| WO2009081105A2 (en) | 2007-12-21 | 2009-07-02 | Ucb Pharma S.A. | Quinoxaline and quinoline derivatives as kinase inhibitors |
| EP3613743B1 (en) * | 2008-01-04 | 2022-03-16 | Intellikine, LLC | Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives |
| CA2714700C (en) | 2008-02-22 | 2013-07-30 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| AU2009219154A1 (en) | 2008-02-29 | 2009-09-03 | Cylene Pharmaceuticals, Inc. | Protein kinase modulators |
| MY183331A (en) | 2008-03-04 | 2021-02-18 | Natco Pharma Ltd | Crystal form of phenylamino pyrimidine derivatives |
| US20090227575A1 (en) | 2008-03-04 | 2009-09-10 | Wyeth | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS |
| JP2011513419A (ja) | 2008-03-06 | 2011-04-28 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
| PE20091617A1 (es) | 2008-03-13 | 2009-11-12 | Boehringer Ingelheim Int | Tiazolil-dihidro-indazoles |
| US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| WO2009117482A1 (en) | 2008-03-19 | 2009-09-24 | Osi Pharmaceuticals, Inc | Mtor inhibitor salt forms |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| JP5628145B2 (ja) | 2008-03-19 | 2014-11-19 | ケムブリッジ・コーポレーション | 新規チロシンキナーゼ阻害剤 |
| EP2276750A2 (en) | 2008-03-27 | 2011-01-26 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
| ES2480994T3 (es) | 2008-03-31 | 2014-07-29 | Genentech, Inc. | Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso |
| WO2009126635A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | 2-amino-benzothiazole derivates useful as inhibitors of rock kinases |
| EP2283013A1 (en) | 2008-04-16 | 2011-02-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
| WO2009129259A2 (en) | 2008-04-16 | 2009-10-22 | Takeda Pharmaceutical Company Limited | Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor |
| PH12012500901A1 (en) * | 2009-11-05 | 2016-08-05 | Rhizen Pharmaceuticals Sa | Novel benzopyran kinase modulators |
| JP5639665B2 (ja) * | 2010-02-12 | 2014-12-10 | エヌサーティー・ファーマシューティカルズ・インコーポレーテッド | Ｓ−ニトロソグルタチオンレダクターゼのクロモン阻害剤 |
| HRP20190128T1 (hr) | 2011-05-04 | 2019-03-08 | Rhizen Pharmaceuticals S.A. | Novi spojevi kao modulatori protein kinaza |
| AU2013255469B2 (en) | 2012-05-04 | 2017-10-12 | Rhizen Pharmaceuticals Sa | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CN109970742A (zh) | 2012-07-04 | 2019-07-05 | 理森制药股份公司 | 选择性PI3Kδ抑制剂 |
| US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
-
2010
- 2010-11-03 PH PH1/2012/500901A patent/PH12012500901A1/en unknown
- 2010-11-03 EA EA201790267A patent/EA036876B1/ru unknown
- 2010-11-03 PT PT108036195T patent/PT2496567T/pt unknown
- 2010-11-03 EP EP16159544.2A patent/EP3050876A3/en not_active Withdrawn
- 2010-11-03 SM SM20170468T patent/SMT201700468T1/it unknown
- 2010-11-03 CA CA2779574A patent/CA2779574C/en active Active
- 2010-11-03 KR KR1020127014647A patent/KR101821768B1/ko active Active
- 2010-11-03 PL PL10803619T patent/PL2496567T3/pl unknown
- 2010-11-03 WO PCT/IB2010/002804 patent/WO2011055215A2/en not_active Ceased
- 2010-11-03 EP EP10803619.5A patent/EP2496567B1/en active Active
- 2010-11-03 SG SG10201500895XA patent/SG10201500895XA/en unknown
- 2010-11-03 CA CA3022722A patent/CA3022722A1/en not_active Abandoned
- 2010-11-03 AP AP2012006294A patent/AP2012006294A0/xx unknown
- 2010-11-03 KR KR1020187001585A patent/KR102012398B1/ko not_active Expired - Fee Related
- 2010-11-03 AU AU2010316780A patent/AU2010316780B2/en active Active
- 2010-11-03 EP EP18196806.6A patent/EP3444242A3/en not_active Withdrawn
- 2010-11-03 ES ES10803619.5T patent/ES2651682T3/es active Active
- 2010-11-03 HU HUE10803619A patent/HUE035059T2/hu unknown
- 2010-11-03 MY MYPI2012002000A patent/MY173795A/en unknown
- 2010-11-03 DK DK10803619.5T patent/DK2496567T3/en active
- 2010-11-03 MX MX2012005301A patent/MX352661B/es active IP Right Grant
- 2010-11-03 BR BR112012010640A patent/BR112012010640A2/pt not_active Application Discontinuation
- 2010-11-03 US US12/938,609 patent/US10442783B2/en not_active Expired - Fee Related
- 2010-11-03 LT LTEP10803619.5T patent/LT2496567T/lt unknown
- 2010-11-03 JP JP2012537454A patent/JP5889795B2/ja active Active
- 2010-11-03 HR HRP20171537TT patent/HRP20171537T1/hr unknown
- 2010-11-03 CN CN201080060611.5A patent/CN102812013B/zh active Active
- 2010-11-03 EA EA201290209A patent/EA027123B1/ru unknown
- 2010-11-03 RS RS20171017A patent/RS56432B1/sr unknown
- 2010-11-03 CN CN201610136199.XA patent/CN105801550B/zh not_active Expired - Fee Related
- 2010-11-03 SI SI201031561T patent/SI2496567T1/en unknown
- 2010-11-03 NZ NZ599830A patent/NZ599830A/en not_active IP Right Cessation
-
2011
- 2011-11-09 US US13/292,746 patent/US8642607B2/en active Active
-
2012
- 2012-05-03 IL IL219585A patent/IL219585A/en active IP Right Grant
- 2012-05-25 ZA ZA2012/03849A patent/ZA201203849B/en unknown
- 2012-06-04 CO CO12093609A patent/CO6551721A2/es active IP Right Grant
-
2013
- 2013-11-26 US US14/090,517 patent/US9018375B2/en active Active
-
2015
- 2015-03-09 US US14/642,423 patent/US9421209B2/en not_active Expired - Fee Related
- 2015-08-17 PH PH12015501806A patent/PH12015501806B1/en unknown
- 2015-10-16 AU AU2015243070A patent/AU2015243070B2/en not_active Ceased
-
2016
- 2016-02-17 JP JP2016027735A patent/JP6385966B2/ja not_active Expired - Fee Related
- 2016-07-13 US US15/208,984 patent/US10538501B2/en not_active Expired - Fee Related
-
2017
- 2017-10-12 CY CY20171101071T patent/CY1119766T1/el unknown
-
2018
- 2018-04-18 JP JP2018079763A patent/JP2018111727A/ja active Pending
-
2019
- 2019-08-30 US US16/557,553 patent/US11858907B2/en active Active
-
2023
- 2023-11-13 US US18/508,085 patent/US20240360095A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510133A5 (https=) | ||
| SI2496567T1 (en) | Novel benzopyran kinase modulators | |
| JP6461118B2 (ja) | ブロモドメイン阻害剤としての新規の置換された二環式化合物 | |
| Gillespie et al. | Antagonists of the human A2A adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo [4, 5-d] pyrimidines | |
| CA3077499C (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd | |
| JP2017538721A (ja) | ブロモドメインの阻害剤 | |
| JP2017505808A5 (https=) | ||
| CN109963854A (zh) | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2016522246A5 (https=) | ||
| WO2015092634A1 (en) | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders | |
| HRP20171610T1 (hr) | Selektivni inhibitori pi3k delta | |
| PH12015501058B1 (en) | Pyrimidine-2,4-diamine derivatives for treatment of cancer | |
| JP2016525078A5 (https=) | ||
| JP2013516393A5 (https=) | ||
| TW200536849A (en) | Substituted heterocycles and the uses thereof | |
| TW200811176A (en) | Dihydropyrazolopyrimidinone derivatives | |
| EA029093B1 (ru) | Соединения и композиции в качестве ингибиторов mek | |
| RU2019101002A (ru) | Производные n-(замещенный фенил)-сульфонамида в качестве ингибиторов киназы | |
| JP2021500340A5 (https=) | ||
| JP2025513483A (ja) | ピラゾール置換シクロペンチルエステル誘導体及びその用途 | |
| ES2837018T3 (es) | Ligandos del receptor D3 de dopamina de 6,7,8,9-tetrahidro-5H-pirido[2,3-d]azepina | |
| CN111511745A (zh) | 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2022519764A (ja) | 二環式スルホンアミド | |
| CN105050602B (zh) | 作为pi3激酶抑制剂的吡啶化合物 | |
| JP2017513910A (ja) | 複素環式化合物およびそのドーパミンｄ１リガンドとしての使用 |